Clinical Trials
12 trialsNCT05916196 2026-06-05
[18F]FES PET/.CT in Uterine Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06180733 2026-05-01
PAM-II
University Medical Center Groningen
Phase 2 Active not recruiting
NCT05758688 2026-03-12
PROPS GYN
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT06369155 2026-03-02
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03668340 2026-01-12
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06331468 2025-12-26
Hypofractionated Radiochemotherapy
University of Kentucky
Phase 2 Recruiting
NCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT06677190 2025-11-05
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06492070 2025-08-27
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
Phase 2 Recruiting
NCT04080284 2025-08-19
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Northwell Health
Phase 2 Completed
NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed